Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.75 |
| ▸ | MGLL | Q99685 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13800284 | 0.87 | PTGDR2 (0.77) | PTGDR2MGLLPKMKDM4EALDH1A1 | |
| SCHEMBL1714126 | 0.86 | PTGDR2 (0.66) | PTGDR2MGLLKDM4EALDH1A1TDP1 | |
| SCHEMBL1714166 | 0.86 | PTGDR2 (1.00) | PTGDR2MGLLKDM4EALDH1A1MEN1 | |
| SCHEMBL13813451 | 0.84 | PTGDR2 (0.87) | PTGDR2 | |
| SCHEMBL1714600 | 0.84 | PTGDR2 (0.87) | PTGDR2 | |
| SCHEMBL28766926 | 0.83 | ALDH1A1 (0.56) | PTGDR2PKMKDM4EALDH1A1ALOX15 | |
| SCHEMBL13800329 | 0.82 | PTGDR2 (0.70) | PTGDR2MGLL | |
| SCHEMBL13800153 | 0.82 | PTGDR2 (0.72) | PTGDR2MGLLMEN1KMT2A | |
| SCHEMBL1714179 | 0.81 | PTGDR2 (0.92) | PTGDR2PKMKDM4EALDH1A1ALOX15 | |
| SCHEMBL1713751 | 0.80 | PTGDR2 (1.00) | PTGDR2MGLLKDM4EALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524715-B2 | Phenoxyacetic acid derivatives useful for treating respiratory diseases | ASTRAZENECA AB (SE) | 2013-09-03 | — | — | US | claimed |
| CN-101107226-B | Phenoxyacetic acid derivatives useful for treating respiratory diseases | ASTRAZENECA AB | 2012-01-18 | — | — | CN | claimed |
| EP-1817282-B1 | PHENOXYACETIC ACID DERIVATIVES USEFUL FOR TREATING RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2011-07-20 | — | — | EP | claimed |
| US-20090149448-A1 | Phenoxyacetic Acid Derivatives Useful for Treating Respiratory Diseases | ASTRAZENECA AB (SE) | 2009-06-11 | — | — | US | claimed |
| EP-1817282-A1 | PHENOXYACETIC ACID DERIVATIVES USEFUL FOR TREATING RESPIRATORY DISEASES | AstraZeneca AB (SE) | 2007-08-15 | — | — | EP | claimed |
| WO-2006056752-A1 | PHENOXYACETIC ACID DERIVATIVES USEFUL FOR TREATING RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2006-06-01 | — | — | WO | claimed |
| US-8524715-B2 | Phenoxyacetic acid derivatives useful for treating respiratory diseases | ASTRAZENECA AB (SE) | 2013-09-03 | — | — | US | disclosed |
| US-8524715-B2 | Phenoxyacetic acid derivatives useful for treating respiratory diseases | ASTRAZENECA AB (SE) | 2013-09-03 | — | — | US | disclosed |
| US-8524715-B2 | Phenoxyacetic acid derivatives useful for treating respiratory diseases | ASTRAZENECA AB (SE) | 2013-09-03 | — | — | US | disclosed |
| CN-101107226-B | Phenoxyacetic acid derivatives useful for treating respiratory diseases | ASTRAZENECA AB | 2012-01-18 | — | — | CN | disclosed |
| EP-1817282-B1 | PHENOXYACETIC ACID DERIVATIVES USEFUL FOR TREATING RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2011-07-20 | — | — | EP | disclosed |
| US-20090149448-A1 | Phenoxyacetic Acid Derivatives Useful for Treating Respiratory Diseases | ASTRAZENECA AB (SE) | 2009-06-11 | — | — | US | disclosed |
| US-20090149448-A1 | Phenoxyacetic Acid Derivatives Useful for Treating Respiratory Diseases | ASTRAZENECA AB (SE) | 2009-06-11 | — | — | US | disclosed |
| US-20090149448-A1 | Phenoxyacetic Acid Derivatives Useful for Treating Respiratory Diseases | ASTRAZENECA AB (SE) | 2009-06-11 | — | — | US | disclosed |
| EP-1817282-A1 | PHENOXYACETIC ACID DERIVATIVES USEFUL FOR TREATING RESPIRATORY DISEASES | AstraZeneca AB (SE) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006056752-A1 | PHENOXYACETIC ACID DERIVATIVES USEFUL FOR TREATING RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149448-A1 | Phenoxyacetic Acid Derivatives Useful for Treating Respiratory Diseases | PAOX, PCCA, PAH | PTGDR2 236/4885MGLL 1505/4885PKM 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.